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Abstract
Chronic tonsillar diseases are an important health problem, leading to large numbers of surgical procedures worldwide.
Little is known about pathogenesis of these diseases. In order to investigate the role of respiratory viruses in chronic
adenotonsillar diseases, we developed a cross-sectional study to determine the rates of viral detections of common
respiratory viruses detected by TaqMan real time PCR (qPCR) in nasopharyngeal secretions, tonsillar tissues and peripheral
blood from 121 children with chronic tonsillar diseases, without symptoms of acute respiratory infections. At least one
respiratory virus was detected in 97.5% of patients. The viral co-infection rate was 69.5%. The most frequently detected
viruses were human adenovirus in 47.1%, human enterovirus in 40.5%, human rhinovirus in 38%, human bocavirus in 29.8%,
human metapneumovirus in 17.4% and human respiratory syncytial virus in 15.7%. Results of qPCR varied widely between
sample sites: human adenovirus, human bocavirus and human enterovirus were predominantly detected in tissues, while
human rhinovirus was more frequently detected in secretions. Rates of virus detection were remarkably high in tonsil
tissues: over 85% in adenoids and close to 70% in palatine tonsils. In addition, overall virus detection rates were higher in
more hypertrophic than in smaller adenoids (p = 0.05), and in the particular case of human enteroviruses, they were
detected more frequently (p = 0.05) in larger palatine tonsils than in smaller ones. While persistence/latency of DNA viruses
in tonsillar tissues has been documented, such is not the case of RNA viruses. Respiratory viruses are highly prevalent in
adenoids and palatine tonsils of patients with chronic tonsillar diseases, and persistence of these viruses in tonsils may
stimulate chronic inflammation and play a role in the pathogenesis of these diseases.
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Introduction
Palatine tonsils and adenoids are prominent secondary
lymphoepithelial organs associated with the upper respiratory
tract, where inhaled antigens first come in contact with host
defense cells [1]. Tonsillar hyperplasia and recurrent tonsillitis are
common chronic diseases that often lead to complications that
include nasal obstruction, recurrent sinusitis, snoring, auditory
tube dysfunction, otitis media, obstructive sleep apnea and
changes in facial growth and behavioral development [2]. These
complications frequently lead to patients undergoing tonsillecto-
my, which still is one of the most commonly performed pediatric
surgical procedures worldwide [3]. Yet, the pathogenesis of
chronic tonsillar diseases is largely unknown. Tonsils and adenoids
harbor bacterial and viral pathogens [4–6], and although bacterial
components of biofilms can be cultured from the surfaces and
crypts of inflamed tonsils and adenoids, their role as causative
agents of adenotonsillar hyperplasia is largely unknown [7].
Recovery of adenovirus and herpesvirus from tonsils and
adenoids has been reported since the 1950s and 1960s [8,9], but
the advent of sensitive molecular methods has made it possible to
detect many other viruses, including those not amenable to
recovery in cell culture [4,5,10]. Nevertheless, systematic studies of
viruses in adenoids and tonsils have been scarce, especially in
association with chronic hypertrophic tonsillar disease. In order to
investigate the role of respiratory viruses in chronic adenotonsillar
diseases we have performed a cross-sectional study in surgical
tissue samples and cavity washes from patients with recurrent
tonsillitis and chronic adenotonsillar hyperplasia. To the best of
our knowledge, this has been the most extensive study of its kind to
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date. The results revealed high rates of virus detection in
adenotonsillar tissues, with divergent virus preponderance in
different sampling sites, possibly owing to different routes of
infection and/or tissue composition. The high rates of detection of
respiratory viruses in adenoids and palatine tonsils of patients with
chronic adenotonsillar disease bring new insights about the
transmission of respiratory viruses and their role in pathogenesis
of chronic adenotonsillar diseases.
Materials and Methods
Patients and Specimen Collections
A total of 121 children (63 boys) 1 to 14 years of age (mean age
5.963.2 years years) were enrolled in the study, all with indication
for tonsillectomy due to tonsillar hypertrophy (60) or recurring
tonsillitis (61), and in the absence of symptoms of acute respiratory
infection.
This cross-sectional study was carried out from May 2010 to
August 2011 and it enrolled patients who underwent tonsillectomy
at the Division of Otorhinolaryngology of the Clinical Hospital of
the University of Sa˜o Paulo School of Medicine, in Ribeira˜o Preto,
Brazil. Exclusion criteria were: presence of symptoms of acute
respiratory infection at the time of surgery and antibiotic
treatment within one month prior to surgery.
Patients were grouped according to palatine tonsil size and
history of prior tonsillar infections as follows:
– RT group: Included 11 patients (9.1%) with 4 to 14 years of
age (mean age 5.91 years) with recurrent tonsillitis (RT)
according to the Paradise criteria: 7 episodes in the last year, 5
episodes/year in the last two years, or 3 episodes/year in the
last 3 years; plus tonsils that occupied less than 50% of the
oropharyngeal airway (Brodsky tonsil size #2).
– TH group: Included 49 patients (40.5%) with 2 to 13 years of
age (mean age 5.85 years) with only tonsillar hyperplasia (TH)
with enlarged tonsils occupying 50–100% of the oropharyngeal
airway (Brodsky tonsil size $2), without history of recurrent
tonsillitis.
– RT/TH group: Included 50 patients (41.3%) with 1 to 14 years
of age (mean 6.33 years) with recurrent tonsillitis and tonsillar
hyperplasia (RT/TH).
– Non RT/TH group: Included 11 patients (9.1%) with 3 to 10
years of age (mean of 7.09 years), with normal size tonsils and
no history of recurrent tonsillitis. These patients presented
tonsils that occupied less than 50% of the oropharyngeal
airway (Brodsky tonsil size #2), but they had OSAS -
obstructive sleep apnea syndrome.
According to adenoid size, as determined by lateral X-ray and/
or nasal endoscopy, the 119 patients who underwent adenoidec-
tomy (2 patients who underwent tonsillectomy did not have
adenoids removed), were grouped as follows:
– Group 1: Included 15 patients (12.6%) with 3 to 13 years of age
(mean of 7 years), with less than 50% airway obstruction.
– Group 2: Included 58 patients (48.7%) with 1 to 14 years of age
(mean of 6.3 years) with 50–75% airway obstruction.
– Group 3: Included 46 patients (38.7%) with 2 to 14 years of age
(mean 5.3 years), with airway obstruction greater than 75%.
Samples obtained during surgery were: a) nasopharyngeal
secretions (NS), consisting of a combination of nasopharyngeal
washes with swabs from mucosal surfaces of adenoids and palatine
tonsils, all three collected from all patients; b) fragment of tissue
from removed adenoids and palatine tonsils; c) peripheral blood.
Tissue fragments were placed in Eagle’s minimal essential medium
(MEM) with 10% fetal bovine serum and 15% antibiotics-
antimycotic solution (penicillin-streptomycin 20,000 U/ml and
amphotericin B 200 mg/mL) (Gibco, Grand Island, NY, USA) and
all samples were transported on ice within less than four hours to
the virology laboratory, where they were processed and tested for
the respiratory viruses.
In the laboratory, the tissue fragments were washed twice with
MEM to remove excess of cells debris and blood, and cut into
portions of approximately 0.5 cm x 0.5 cm using RNAse free
surgical material. These fragments were macerated in Trizol
(Invitrogen, Carlsbad, CA, USA) and in one preservative solution
(RNA later – Invitrogen, Carlsbad, CA, USA) for further nucleic
acids extraction. All the secretions were treated with antibiotics
and antimycotics (Gibco, Grand Island, NY, USA) for 1 hour and
aliquoted in an equal volume of freezing medium (MEM, 20%
FBS and 15% glycerol) and in the triple volume of Trizol
(Invitrogen, Carlsbad, CA, USA).
After processing, all samples were aliquoted and kept at 270uC
until further testing.
Ethics Statement
The project was based on analysis of clinical samples from
patients sent for tonsillectomy, and all obtained tissues would
normally excised from all patients. The study was conducted
according to the principles expressed in the Declaration of
Helsinki and was approved by the Ethics Review Committee of
the Hospital das Clı´nicas de Ribeira˜o Preto (Number 10466/2008)
and a written informed consent was obtained from all parents and
guardians prior to enrollment.
Detection of Respiratory Viruses
Nucleic acids were extracted from 200 mL of nasopharyngeal
secretions using the QIAamp Min Elute Virus Spin Kit (Qiagen
GmbH, Hilden, Germany); from ,30 mg of tissue using the
AllPrep DNA/RNA mini kit (Qiagen GmbH, Hilden, Germany);
and from 1 mL of peripheral blood using the QIAamp RNA and
DNA blood mini kit (Qiagen GmbH, Hilden, Germany), all
following manufacturer’s instructions.
Samples were tested by TaqMan real-time PCR (qPCR) for the
presence of genomes of human bocavirus (HBoV), human
adenovirus (HAdV), rhinovirus (HRV), enterovirus (HEV), human
respiratory syncytial virus (HRSV) A and B, metapneumovirus
(HMPV) A and B, human Influenza virus (FLU) A and B
(including H1N1 2009), parainfluenza virus (HPIV) 1 and 3, and
coronavirus (HCoV) OC43 and 229E. All qPCR assays were done
on Thermocycler 7300 (Applied Biosystems, Foster City, CA,
USA) with specific primers and probes (Table S1). qPCR for b-
actin and RNAseP housekeeping genes was done in all samples.
The qPCR assays using two sets primers for different clusters of
HRV types, HRSV subgroups A and B, and HCoV types OC43
and 229E, were done in duplex format. The remaining qPCR
assays done with one set of primers per reaction for HAdV,
HBoV, HMPV A, HMPV B, FLU A, FLU B, HPIV 1, HPIV 3,
RNAseP and b-Actin were done separately. For the RNA viruses
(HRV, FLU, HPIV, HRSV, HMPV, HEV and HCoV) reverse
transcription was done prior to qPCR using 1 mg of extracted
RNA primed with random hexamers, with Multiscribe reverse
transcriptase (Applied Biosystems, Foster City, CA, USA) follow-
ing protocol proposed by the manufacturer. Duplex qPCR assays
were done in a final volume of 15 mL with 3 ml of cDNA, 10 mM
forward and reverse primers, 5 mM probe, 7.5 ml of TaqMan
master mix (Applied Biosystems, Foster City, CA, USA), with the
Viruses in Chronic Adenotonsillar Diseases
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following parameters: 95uC for 10 minutes, followed by 45 cycles
of 95uC for 15 seconds and 60uC for 1 minute. The qPCR assays
with a single pair of primers per reaction were done in a final
volume of 10 mL with 3 ml of cDNA, 10 mM forward and reverse
primers, 5 mM probe, 5 ml of TaqMan master mix, with the
following parameters: 95uC for 10 minutes, followed by 45 cycles
of 95uC for 15 seconds, and 60uC for 1 minute, except when the
target was FLU A, HEV or HMPV A and B, when the parameters
were: 95uC for 10 minutes, followed by 45 cycles of 95uC for 15
seconds, 55uC for 30 seconds, and 60uC for 1 minute. For the
DNA viruses, qPCR was done with 300 ng of extracted DNA in a
final volume of 10 mL, containing 10 mM forward and reverse
primers, 5 mM probe and 5 mL of TaqMan master mix, using the
same cycling parameters as for the RNA viruses. Applicable
measures to prevent contamination of PCR reactions were taken
in this study, including sample handling and reaction mix
preparation in separate rooms. In addition, all qPCR plates
included appropriate negative controls, matched to every step of
clinical sample treatment. The negative controls were RT-qPCR
products from RNA or DNA extracted from cultures of uninfected
Hela cells; RT-qPCR product from ultrapure water; and just
qPCR product from ultrapure water.
Statistical Analysis
Chi-square and Exact Chi-square tests were used to compare
patient groups and viral detection rates in relation to different
parameters analyzed. Agreement between samples was tested
using Kappa test, followed by the calculation of odds ratios.
Analysis of presence of viruses in relation to ages and clinical
conditions were done with Mann-Whitney test. Analyses were
conducted using the SPSS software (Statistical Package for the
Social Sciences), version 17(SPSS Inc.). A P value of #0.05 was
chosen for significance.
Results
Virus Detection
This study included nasopharyngeal secretions (NS), fragments
of tissue from adenoids and palatine tonsils and peripheral blood
from a total of 121pediatric patients with indication of tonsillec-
tomy due tonsillar hyperplasia or recurring tonsillitis. The overall
frequency of virus detection was very high: 118 of 121 patients
(97.5%) had at least one virus detected in at least one clinical
sample (Figure 1a and Table 1). Only 3 patients had no respiratory
virus detected by qPCR. The highest rate of virus detection was
found in adenoids (85.7%), followed by NS (78.5%), palatine
tonsils (68.6%), and peripheral blood (1%) (Figure 1a). Interest-
ingly, when both kinds of tonsils were taken together, 112 (92.6%)
of the patients were positive for at least one virus in at least one of
the tonsils.
Considering the results of virus detection altogether, HAdV was
the most often detected agent, in 57 (47.1%) patients, followed by
HEV in 49 (40.5%), HRV in 46 (38%), HBoV in 36 (29.8%),
HMPV in 21 (17.4%), HRSV in 19 (15.7%), FLU in 7 (5.8%),
HPIV in 6 (4.9%) and HCoV in 4 (3.3%) (Figure 1b). Frequencies
of detection of viruses in all sites are summarized in Table 1.
The detection of specific viruses notably varied among sample
sites, indicating that respiratory viruses have different tissue
tropisms, even when we compared pharyngeal and palatine
tonsils. HAdV and HBoV were detected in adenoids more often
than in others sites, whereas HEV and HRV were more frequently
detected respectively in palatine tonsils and NS. Of the 119
patients from whom samples of all sites were obtained, 59 (49.6%)
had at least one virus detected simultaneously at three sample
kinds. In only 15 patients (12.6%) viruses were detected in only
one sample (Table 2).
The virus most frequently detected in NS was HRV, in 42
(34.7%) patients, followed by HAdV (29.8%), HEV (18.2%),
HBoV (11.6%), and all other viruses were detected in frequencies
lower than 10%. In the palatine tonsils, HEV was found in 45
samples (37.2%), followed by HAdV in 29 samples (24%), HRV in
15 samples (12.4%), and all other viruses were detected in
frequencies lower than 10%.
Overall virus detection rates were notably higher in adenoids,
where the most frequent virus detected was HAdV in 42.9%,
followed by HEV in 37 (30.6%), HRV in 30 (24.8%) and HBoV in
28 (23.1%) patients. The only virus detected by qPCR in the
peripheral blood was HBoV, found in two patients (Figure 1b).
HAdV was more frequently detected in the adenoids, although
simultaneous detection in other sampling sites was very frequent.
Only 6 of all 57 HAdV-positive patients had the virus detected
only in sites different from the adenoids (Table 2). The kappa
value for agreement between HAdV detection in adenoids and
palatine tonsils was 0.4 (95% confidence interval: 0.24–0.56,
p,0.001), and for detection in adenoids and secretions it was 0.71
(95% confidence interval: 0.58 to 0.84, p,0.001), respectively.
Detection of HAdV in adenoid increased by more than 10 times
the chance of detecting it in palatine tonsils (OD: 10.35, 95%
confidence interval: 3.57 to 30.01, p,0.001) and NS (OD: 294.76;
95% confidence interval:17.17 to 5061.00, p,0.001).
Similarly, HBoV was also more frequently detected in adenoids
than in other sites, and 52.8% of patients had HBoV detectable
only in the adenoid tissue. Detection of HBoV in adenoids was
associated with simultaneous detection of that virus in palatine
tonsils (kappa = 0.17; 95% confidence interval: 0.01–0.35;
p = 0.03; OD = 7.42; 95% confidence interval: 1.28–42.95;
p = 0.01) and NS (kappa = 0.27; 95% confidence interval: 0.06–
0.47; p = 0.004; OD = 5.67; 95% confidence interval: 1.78–18.17;
p = 0.002). In just 2 patients HBoV was detected only in the
palatine tonsils, but not in the adenoids.
NS was the only sample positive for HRV in 34.8% of patients,
and in only 4 patients HRV was detected exclusively in samples
other than NS (Table 2). Detection HRV in NS was associated
with its presence in both palatine tonsils [kappa = 0.38, 95%
confidence interval: 0.22 to 0.54; p,0.001) and adenoids
[kappa = 0.61; 95% confidence interval: 0.46 to 0.76; p,0.001).
Detection of HRV in nasopharyngeal secretions increased the
chance of detecting this virus by more than 29 times for adenoids
(relative risk = 29.66; 95% confidence interval: 9.08 to 96.86;
p,0.001) and 39 times for tonsils (relative risk = 39.00; 95%
confidence interval: 4.90 to 310.37; p,0.001).
While HAdV and HBoV were more frequently detected in
adenoids, enteroviruses were significantly more frequent in
palatine tonsils. Of 49 patients positive for HEV, 45 (92%) had
positivity in palatine tonsils, which was strongly correlated with
their presence in adenoids (kappa = 0.7; confidence interval 0.54 to
0.84; p,0.001) and nasopharyngeal secretions (kappa = 0.51;
confidence interval: 0.35 to 0.67; p,0.001). Thus, the detection
of HEV in palatine tonsils increased the chance of finding HEV in
adenoids by 48.13 times (95% confidence interval: 14.42 to
160.57; p,0.001) and in NS by 65.63 times (95% confidence
interval: 8.38 to 513.90; p,0.001). Interestingly, in 11 of 45
(24.5%) patients with HEV detectable in palatine tonsils, that site
was the only one positive for HEV, as opposed to 4 (8.8%) patients
in whom HEV was detected solely in sites other than palatine
tonsils (Table 2).
For all remaining viruses the rates of detection were lower,
hampering comparisons between sampling sites.
Viruses in Chronic Adenotonsillar Diseases
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Viral-coinfections
High rates of viral co-infections were obtained in this patient
group. Of 118 patients positive for any respiratory virus, 82
(69.5%) had more than one virus. Of the 82 patients who had
more than one detectable agent, 47 (57%) had 2, 26 (32%) had 3,
8 (9.7%) had 4, and 1 patient had five simultaneously detectable
viruses (Figure 2). The viruses most frequently detected as single
agents were HEV in 13 (11%), followed by HRV in 10 (8.5%) and
HAdV in 5 (4.3%) patients, respectively. Other viruses were found
as single agents in frequencies lower than 3% (Table 3).
The rates of detection of more than one virus per sample site
were lower in palatine tonsils than in adenoids (44.5%) and NS
(31.4%) (Figure 2). In only 25 patients (20.7%), viral co-infections
were detected in palatine tonsils. The higher frequency of HEV as
exclusive agent was in palatine tonsils, where HEV was detected
alone in 33 patients (27.3%) (Figure 2). The viruses most
frequently detected as single agents in NS and adenoids were
respectively: HRV in 19 (15.9%) patients, and HAdV in 14
(11.6%) patients.
Although the frequencies of viral co-infections for specific
viruses varied among sample sites, DNA viruses (HAdV and
HBoV) were more often detected as part of co-infections than
RNA viruses (Figure 3). HBoV was the single most frequently
detected in co-infection with other agents regardless of sample site
(Table 3). Conversely, HEV was the least frequently detected virus
in co-infection with other agents, in particular in palatine tonsils
(Figure 3).
The virus co-infections observed in this study generally involved
DNA viruses in combination with some RNA virus, most notably
HRV and HEV (Table 3). The most frequent co-infection
detected was HAdV with HEV, in 9 patients, of whom 8 had
HAdV in the adenoid and HEV in the palatine tonsil (Table 3).
Figure 1. Frequencies of virus detection in patients with chronic adenotonsillar diseases. (A) Overall frequencies of virus detection by
qPCR in different sample sites of 121 patients with chronic adenotonsillar disease. (B) Frequencies of detection of each tested virus by qPCR at
different sites in 121 patients with chronic adenotonsillar disease.
doi:10.1371/journal.pone.0042136.g001
Table 1. Viral prevalence determined by qPCR in the different sample sites in 121 patients with chronic adenotonsillar disease.
VIRUS
Any Site*
N (%)
Adenoids**
N (%)
Palatine Tonsils
N (%)
NS
N (%)
Peripheral Blood
N (%)
All Viruses# 118 (97.5) 102 (85.7) 83 (68.6) 95 (78.5) 2 (1.6)
HAdV 57 (47.1) 51 (42.8) 29 (23.9) 36 (29.8) 0 (0.0)
HBoV 36 (29.7) 28 (23.5) 6 (4.9) 14 (11.6) 2 (1.6)
HRV 46 (38.0) 30 (25.2) 15 (12.4) 42 (34.7) 0 (0.0)
HEV 49 (40.5) 37 (31.1) 45 (37.2) 22 (18.2) 0 (0.0)
HRSV 19 (15.7) 14 (11.8) 3 (2.5) 12 (9.9) 0 (0.0)
HMPV 21 (17.3) 10 (8.4) 13 (10.7) 9 (7.4) 0 (0.0)
FLU 7 (5.8) 3 (2.5) 1 (0.8) 5 (4.1) 0 (0.0)
HPIV 6 (4.9) 4 (3.7) 3 (2.5) 1 (0.8) 0 (0.0)
HCoV 4 (3.3) 4 (3.7) 0 (0.0) 4 (3.3) 0 (0.0)
*Any site: results of viral detection at any of the sites analyzed.
*Adenoids were obtained only from 119 of the total of 121 patients included in this study.
#All viruses: positivity for at least one virus by qPCR.
doi:10.1371/journal.pone.0042136.t001
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Other frequent co-infections were of HRV (usually in the NS) with
HAdV (usually in adenoid); and of HBoV (usually in adenoids)
with HEV (usually in palatine tonsils). It is noteworthy that of 82
patients in whose samples more than one virus were detected, only
13 (15.8%) had co-infections involving exclusively RNA viruses.
Frequencies of specific combinations of co-infecting viruses
varied among sample sites. In adenoids, co-infections more
frequently involved HAdV + HEV, HAdV + HRV, and HAdV
+ HBoV + HRV, respectively in 8 (6.7%), 6 (5%) and 5 (4.2%)
patients. The most frequent virus associations in palatine tonsils
and NS were, respectively, HAdV + HEV, and HAdV + HRV.
Clinical Features
All patients enrolled in this study underwent tonsillectomy due
to adenotonsillar hypertrophy or recurring tonsillitis. Of 121
patients, 16 (12.4%) also had otitis media with effusion, 61 (50.5%)
had apnea, and 33 (27.3%) reported underlying conditions,
including asthma in 5 and symptoms of allergy in 19.
The presence of allergic symptoms, bronchial asthma and
recurrent otitis media with effusion were not significantly
associated with the presence of specific respiratory viruses, except
for an association of HRSV in adenoids with reported allergy
(x2 = 4.61, p = 0.04).
Although global virus detection rates in adenoids and palatine
tonsils were higher in younger patients (Z = 2.34, p = 0.02 for
adenoids, and Z = 2.79, p = 0.005 for palatine tonsils), when that
analysis was done for specific agents, significance was noted only
for HBoV (Z = 3.67, p,0.005).
Virus detection, both overall and agent-specific, was not
associated with recurrent tonsillitis (Table 4). In fact, rates of
virus detection were not significantly different (x2 = 3.01, p = 0.10)
in children with recurrent tonsillitis and/or severe tonsillar
hypertrophy (.70%), as compared to children without recurrent
tonsillitis and in those with lower degrees of palatine tonsil
hypertrophy (45.45%).
Overall rates of virus detection were not significantly different
between patients with large (Brodsky$3) and small palatine tonsils
(Brodsky #3) (x2 = 3.58, p = 0.06). However, there was an
association between higher virus detection rates with larger
palatine tonsils in the specific case of HEV, since this agent was
detected in palatine tonsils from 40 of 98 (40.8%) patients with
higher hypertrophy degrees (Brodsky $3), and in 5 of 22 (22.7%)
patients with less severe hypertrophy (Brodsky ,3) (x2 = 4.09,
Table 2. Numbers of positive samples taken from different
sites in 119 patients with chronic adenotonsillar disease from
whom samples were obtained from all sites.
PT +
Ad +
PT +
Ad 2
PT 2
Ad +
PT 2
Ad 2 Total*
All
viruses
NS+ 59 5 24 6
NS2 14 4 5 2 117
HAdV NS+ 18 1 17 0
NS2 5 5 11 62 57
HBoV NS+ 3 0 5 6
NS2 1 2 19 83 36
HRV NS+ 14 0 12 16
NS2 1 0 3 73 46
HEV NS+ 20 1 1 0
NS2 13 11 3 70 49
Adenoids were not available from two patients, one of whom was negative for
all tested viruses, while the other had HRSV in NS.
PT: palatine tonsil; Ad: adenoid; NS: nasopharyngeal secretion.
*Total number of positive samples.
doi:10.1371/journal.pone.0042136.t002
Figure 2. Frequencies of virus co-infections in different sample sites in 121 patients with chronic adenotonsillar diseases.
doi:10.1371/journal.pone.0042136.g002
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Table 3. Frequencies of specific viruses and viral associations at different sample sites in 121 patients with chronic adenotonsillar
diseases.
Virus Detection Any Site* N (%) NS N (%) PT N (%) Ad** N (%)
Single infection HAdV 5 (4.1) 11 (9.1) 11 (9.1) 14 (11.8)
HBoV 2 (1.6) 3 (2.5) 2 (1.6) 3 (2.5)
HRV 10 (8.2) 19 (15.7) 5 (4.1) 10 (8.4)
HEV 13 (10.7) 13 (10.7) 33 (27.3) 14 (11.8)
HRSV 2 (1.6) 4 (3.3) 2 (1.6) 4 (3.3)
HMPV 3 (2.5) 3 (2.5) 4 (3.3) 2 (1.6)
FLU 1 (0.8) 1 (0.8) 0 (0.0) 1 (0.8)
HPIV 0 (0.0) 2 (1.6) 1 (0.8) 0 (0.0)
HCoV 0 (0.0) 1 (0.8) 0 (0.0) 1 (0.8)
TOTAL 36 (29.7) 57 (47.1) 58 (47.9) 49 (41.1)
Dual infection HAdV + HRV 8 (6.6) 9 (7.4) 4 (3.3) 6 (5.0)
HAdV + HEV 9 (7.4) 1 (0.8) 7 (5.8) 8 (6.6)
HBoV + HEV 7 (5.8) 2 (1.6) 0 (0.0) 3 (2.5)
HEV + HRSV 4 (3.3) 0 (0.0) 0 (0.0) 4 (3.3)
HBoV + HRV 3 (2.5) 1 (0.8) 1 (0.8) 1 (0.8)
HAdV + HBoV 2 (1.6) 3 (2.5) 1 (0.8) 3 (2.5)
HAdV + HRSV 3 (2.5) 2 (1.6) 0 (0.0) 1 (0.8)
HRV + HMPV 2 (1.6) 2 (1.6) 2 (1.6) 0 (0.0)
HRV + HCoV 2 (1.6) 2 (1.6) 0 (0.0) 1 (0.8)
HAdV + HMPV 1 (0.8) 0 (0.0) 1 (0.8) 1 (0.8)
HBoV + HRSV 1 (0.8) 0 (0.0) 0 (0.0) 1 (0.8)
HBoV + FLU 1 (0.8) 0 (0.0) 0 (0.0) 1 (0.8)
HRV + HPIV 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0)
HRV + FLU 1 (0.8) 1 (0.8) 0 (0.0) 0 (0.0)
HEV + HMPV 1 (0.8) 1 (0.8) 1 (0.8) 0 (0.0)
HEV + HPIV 1 (0.8) 0 (0.0) 0 (0.0) 1 (0.8)
HMPV + HPIV 0 (0.0) 0 (0.0) 1 (0.8) 0 (0.0)
HRV + HRSV 0 (0.0) 1 (0.8) 1 (0.8) 0 (0.0)
HRSV + FLU 0 (0.0) 1 (0.8) 0 (0.0) 0 (0.0)
TOTAL 47 (38.8) 26 (21.5) 19 (15.7) 31 (26.0)
Triple Infection HAdV + HBoV + HEV 4 (3.3) 2 (1.6) 1 (0.8) 3 (2.5)
HAdV + HBoV + HRV 5 (4.1) 1 (0.8) 0 (0.0) 5 (4.2)
HAdV + HRV + HMPV 6 (4.9) 2 (1.6) 2 (1.6) 3 (2.5)
HAdV + HEV + HMPV 2 (1.6) 1 (0.8) 2 (1.6) 0 (0.0)
HAdV + HRV + HRSV 2 (1.6) 2 (1.6) 0 (0.0) 2 (1.6)
HAdV + HBoV + HRSV 1 (0.8) 1 (0.8) 0 (0.0) 0 (0.0)
HAdV + HEV + FLU 1 (0.8) 1 (0.8) 0 (0.0) 0 (0.0)
HAdV + HEV + HPIV 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0)
HAdV + HRSV + FLU 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0)
HBoV + HRV + HRSV 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0)
HBoV + HMPV + HPIV 1 (0.8) 0 (0.0) 0 (0.0) 1 (0.8)
HEV + HRSV + FLU 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0)
HBoV + HRV + HCoV 0 (0.0) 1 (0.8) 0 (0.0) 1 (0.8)
HBoV + HPIV + FLU 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.8)
HAdV + HBoV + HMPV 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.8)
HBoV + HEV + HPIV 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.8)
HRV + HEV + HRSV 0 (0.0) 1 (0.8) 0 (0.0) 0 (0.0)
TOTAL 26 (21.5) 12 (9.9) 5 (4.1) 18 (14.8)
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Table 3. Cont.
Virus Detection Any Site* N (%) NS N (%) PT N (%) Ad** N (%)
Quadruple infection HAdV + HBoV + HRV + HMPV 2 (1.6) 0 (0.0) 0 (0.0) 0 (0.0)
HAdV + HBoV + HEV + HCoV 1 (0.8) 0 (0.0) 0 (0.0) 1 (0.8)
HAdV + HBoV + HEV + HMPV 1 (0.8) 0 (0.0) 0 (0.0) 1 (0.8)
HAdV + HBoV + HRV + HRSV 1 (0.8) 0 (0.0) 0 (0.0) 1 (0.8)
HAdV + HEV + HRSV + HMPV 1 (0.8) 0 (0.0) 0 (0.0) 1 (0.8)
HBoV + HRV + HMPV + HCoV 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0)
HBoV + HEV + HPIV + FLU 1 (0.8) 0 (0.0) 1 (0.8) 0 (0.0)
TOTAL 8 (6.6) 0 (0.0) 1 (0.8) 4 (3.3)
One patient had co-infection with five viruses: HBoV + HRV + HEV + HRSV + HPIV; PT: palatine tonsil; Ad: adenoid tissue; NS: nasopharyngeal secretion.
*The indicated single virus or combination was the only identified at any of the sites in the patient.
**Adenoids were obtained only from 119 of the total of 121 patients included in this study.
doi:10.1371/journal.pone.0042136.t003
Figure 3. Frequencies of virus co-infections associated with each analyzed viruses at different sample sites in 121 patients with
chronic adenotonsillar diseases. (A) Overall number of virus co-infections. (B) Number of virus co-infections detected in nasopharyngeal
secretions. (C) Number of virus co-infections detected in palatine tonsils. (D) Number of virus co-infections detected in adenoids.
doi:10.1371/journal.pone.0042136.g003
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p = 0.05). Rates of detection of other viruses were similar between
patients with larger and smaller palatine tonsils (Table 4).
Overall rates of virus detection in adenoids were higher in
patients with more severely enlarged adenoids (Table 5). The
Table 4. Demographic data and virus detection frequencies in patients according to categories of adenotonsillar disease.
Clinical feature/virus detection
RT
N (%)
TH
N (%)
Non RT-TH
N (%)
RT/TH
N (%)
Patients (N) 11 (9.09) 49 (40.49) 11 (9.09) 50 (41.33)
Females 7 (63.63) 22 (44.89) 2 (18.18%) 27 (54%)
Age (mean in years) 5.91 5.85 7.09 6.33
All Viruses + 11 (100) 48 (97.96) 10 (90.90) 49 (98)
virus co-infections + 8 (72.72) 33 (67.34) 7 (63.63) 34 (68)
Virus + in palatine tonsils 8 (72.72) 34 (69.38) 5 (45.45) 36 (72)
Virus co-infections in palatine tonsils 1 (9.09) 8 (16.32) 4 (36.36) 12 (24)
HAdV + 5 (45.45) 20 (40.81) 6 (54.54) 26 (52)
HAdV + isolated 1 (9.09) 1 (2.04) 1 (9.09) 2 (4)
HAdV + in palatine tonsils 3 (27.27) 10 (20.41) 3 (27.27) 13 (26)
HAdV + isolated in palatine tonsils 2 (18.18) 2 (4.08) 0 (0) 7 (14)
HBoV + 3 (27.27) 16 (32.65) 1 (9.09) 16 (32)
HBoV + isolated 0 (0) 1 (2.05) 0 (0) 1 (2)
HBoV + in palatine tonsils 1 (9.09) 2 (4.08) 0 (0) 3 (6)
HBoV + isolated in palatine tonsils 1 (9.09) 0 (0) 0 (0) 1 (2)
HRV + 3 (27.27) 16 (32.65) 4 (36.36) 23 (46)
HRV + isolated 2 (18.18) 5 (10.20) 0 (0) 3 (6)
HRV + in palatine tonsils 1 (9.09) 4 (8.16) 3 (27.27) 7 (14)
HRV + isolated in palatine tonsils 1 (9.09) 3 (6.12) 0 (0) 1 (2)
HEV + 5 (45.45) 23 (46.94) 2 (27.27) 19 (38)
HEV + isolated 0 (0) 6 (12.24) 0 (0) 7 (14)
HEV + in palatine tonsils* 4 (36.36) 23 (46.94) 1 (9.09) 17 (34)
HEV + isolated in palatine tonsils* 3 (27.27) 18 (36.73) 0 (0) 12 (24)
HRSV + 3 (27.27) 8 (16.32) 3 (27.27) 5 (10)
HRSV + isolated 0 (0) 1 (2.04) 0 (0) 1 (2)
HRSV + in palatine tonsils 0 (0) 1 (2.04) 1 (9.09) 1 (2)
HRSV + isolated in palatine tonsils 0 (0) 1 (2.04) 0 (0) 1 (2)
HMPV + 1 (9.09) 3 (6.12) 3 (27.27) 14 (28)
HMPV + isolated 0 (0) 1 (2.04) 1 (9.09) 1 (2)
HMPV + in palatine tonsils 0 (0) 2 (4.08) 2 (18.18) 9 (18)
HMPV + isolated in palatine tonsils 0 (0) 1 (2.04) 1 (9.09) 2 (4)
FLU + 1 (9.09) 4 (8.16) 1 (9.09) 1 (2)
FLU + isolated 0 (0) 0 (0) 1 (9.09) 0(0)
FLU + in palatine tonsils 0 (0) 0 (0) 0 (0) 1(2)
FLU + isolated in palatine tonsils 0 (0) 0 (0) 0 (0) 0(0)
HPIV + 0 (0) 3 (6.12) 0 (0) 3 (6)
HPIV + isolated 0 (0) 0 (0) 0 (0) 0 (0)
HPIV + in palatine tonsils 0 (0) 1 (2.04) 0 (0) 2 (4)
HPIV + isolated in palatine tonsils 0 (0) 1 (2.04) 0 (0) 0 (0)
HCoV + 0 (0) 1 (2.04) 0 (0) 3 (6)
HCoV + isolated 0 (0) 0 (0) 0 (0) 0 (0)
HCoV + in palatine tonsils 0 (0) 0 (0) 0 (0) 0 (0)
HCoV + isolated in palatine tonsils 0 (0) 0 (0) 0 (0) 0 (0)
RT: Recurrent Tonsillitis; TH: Tonsilar Hypertrophy (Brodsky grade .3); non RT/TH: patients with smaller size tonsils (less than Brodsky 3) and without recurrent tonsillitis;
RT/TH: Recurrent Tonsillitis and Tonsilar Hypertrophy.
*p#0.05.
doi:10.1371/journal.pone.0042136.t004
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proportion of patients with larger adenoids (nasopharyngeal
obstruction $75%) was significantly higher (x2 = 3.78, p = 0.05)
in patients with virus detected in the adenoidal tissue (43/102,
42.2%) than in patients without virus in adenoids (3/17, 17.6%).
Patients with virus in adenoid tissue had a chance 3.4 times higher
of having a high degree of adenoid hypertrophy (75–100%) than
those without virus detected there (OD = 3.4; confidence interval:
0.92–12.57; p = 0.05). Although HEV was frequently detected in
adenoids from patients with nasopharyngeal obstruction $75%
(x2 = 3.65, p = 0.06), no single virus was individually associated
with large adenoids (75% to 100% nasopharyngeal obstruction).
Discussion
To the best of our knowledge, this has been the most
comprehensive study of respiratory viruses in chronic adenoton-
sillar diseases of children so far conducted. The study was based on
sensitive molecular assays to detect respiratory viruses in sets of
samples prospectively collected from children with a full spectrum
of chronic adenotonsillar diseases requiring tonsillectomy. The
observed frequency of respiratory virus genomes detected in
97.5% of the children is remarkably high. Such staggering
observation is novel and should be regarded in the light of the
high prevalence of adenotonsillar diseases, pondering the possible
roles that persistence of common respiratory virus may play on
their pathogenesis.
Testing the nucleic acid extracts obtained from macerated
fragments of upper respiratory lymphoepithelial tissues by qPCR
revealed an array of respiratory viral genomes in over 85% of
adenoids and close to 70% of palatine tonsils. Considering that the
children had no symptoms of acute respiratory infections, these
proportions of detection in tissues are by all means extremely high.
Lymphoid tissues associated with the upper respiratory tract
have been recognized as sites of latency/persistency of such agents
as Epstein-Barr virus, human herpes virus 6, HIV, measles virus,
picornaviruses, human bocavirus and human papillomavirus-16
[4,5,10–14]. However, large studies of the presence of the most
common respiratory viruses in lymphoepithelial tissues damaged
by chronic inflammation or hypertrophy are virtually lacking,
what underscores the novelty of the presently reported findings.
While detection of DNA virus genomes (HAdV and HBoV) in
association with lymphoepithelial organs is not novel, such is not
the case of detecting respiratory RNA viruses, for which the
existence of persistency and latency is far from clear. Therefore,
the most surprising findings were the high frequencies of detection
of the picornaviruses HRV and HEV, both detected in
approximately 40% of the children, in the absence of discernible
clinical features of acute respiratory infection. When HRV and
HEV were taken together, the frequencies of picornavirus
detection in adenoids and palatine tonsils were respectively
55.4% and 49.6%, showing that these agents together can be
present in lymphoepithelial tissues in up to one half of subjects
with chronic tonsillar hypertrophy. However, when considering
HRV and HEV separately, as made possible with specific primers
and probes by qPCR, interesting distinct features become evident.
Detection of HRV in nasopharyngeal secretions was highly
frequent (34.7%), and was associated with an increase of 30–40
times in the chance of finding it also in tonsils. Indeed, in only 4 of
46 HRV-positive patients (8.7%), the virus was detected only in
tonsils, without concurrent detection in nasopharyngeal secretions.
In contrast, detection of HEV in palatine tonsils was significantly
more frequent than in adenoids and nasopharyngeal secretions
and, conversely, in only 4 of 49 HEV-positive patients (8.2%) the
virus was detected in sampling sites either than palatine tonsils. A
tropism of HEV for palatine tonsils is illustrated by this site being
the only HEV-positive site in 25% of all 45 patients with HEV in
palatine tonsils.
Table 5. Demographic data and virus detection frequencies
in patients according to adenoid sizes.
Clinical feature/virus detection 0–50% 50–75% 75–100%
Patients (N) 15 (10.08) 58 (48.74) 46 (38.66)
Females 4 (26.66) 31 (55.5) 22 (47.82)
Age (mean in years)* 7.0 6.31 5.26
All Viruses + 15(100) 56 (96.55) 46 (100)
virus co-infections + 11 (73.33) 35 (60.34) 35 (76.08)
Virus + in adenoids* 11 (73.3) 48 (82.75) 43 (93.47)
Virus co-infections in adenoids 5 (33.33) 21 (36.20) 27 (58.69)
HAdV + 7 (46.66) 28 (48.27) 21(45.65)
HAdV + isolated 1 (6.66) 2 (3.44) 2 (4.34)
HAdV + in adenoids 7 (46.66) 24 (41.38) 20 (43.47)
HAdV + isolated in adenoids 4 (26.66) 7 (12.06) 3 (6.52)
HBoV + 4(26.66) 17 (29.31) 15 (32.60)
HBoV + isolated 0 (0) 2 (3.44) 0 (0)
HBoV + in adenoids 3 (20.0) 13 (22.41) 12 (26.08)
HBoV + isolated in adenoids 0 (0) 2 (3.44) 1 (2.17)
HRV + 8 (53.33) 22 (37.93) 16 (34.78)
HRV + isolated 3 (20.0) 5 (8.62) 2 (4.34)
HRV + in adenoids 3 (20.0) 17 (29.31) 10 (21.74)
HRV + isolated in adenoids 1 (6.66) 7 (12.06) 2 (4.34)
HEV + 7 (46.66) 21 (36.20) 21 (45.65)
HEV + isolated 0 (0) 8 (13.79) 5 (10.87)
HEV + in adenoids 3 (20.0) 15 (25.86) 19 (41.30)
HEV + isolated in adenoids 0 (0) 9 (15.51) 5 (10.87)
HRSV + 2 (13.33) 7 (12.06) 9 (19.56)
HRSV + isolated 0 (0) 1 (1.72) 1 (2.17)
HRSV + in adenoids 0 (0) 6 (10.34) 8 (17.39)
HRSV + isolated in adenoids 0 (0) 1 (1.72) 3 (6.52)
HMPV + 4 (26.66) 7 (12.06) 10 (21.74)
HMPV + isolated 0 (0) 2 (3.44) 1 (2.17)
HMPV + in adenoids 2 (13.33) 1 (1.72) 7 (15.21)
HMPV + isolated in adenoids 1 (6.66) 0 (0) 1 (2.17)
FLU + 1 (6.66) 5 (8.62) 1 (2.17)
FLU + isolated 0 (0) 1 (1.72) 0 (0)
FLU + in adenoids 0 (0) 3 (5.17) 0 (0)
FLU + isolated in adenoids 0 (0) 1 (1.72) 0 (0)
HPIV + 2 (13.33) 1 (1.72) 3 (6.52)
HPIV + isolated 0 (0) 0 (0) 0 (0)
HPIV + in adenoids 1 (6.66) 1 (1.72) 2 (4.34)
HPIV + isolated in adenoids 0 (0) 0 (0) 0 (0)
HCoV + 0 (0) 1 (1.72) 3 (6.52)
HCoV + isolated 0 (0) 0 (0) 0 (0)
HCoV + in adenoids 0 (0) 1 (1.72) 3 (6.52)
HCoV + isolated in adenoids 0 (0) 0 (0) 1 (2.17)
*p#0.05.
Obs: Adenoids were not available from two patients.
doi:10.1371/journal.pone.0042136.t005
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The frequent finding of picornaviruses in adenoid and palatine
tonsil tissues in the present study expands on findings of a previous
study done in Finland [10]. In that study a very high frequency of
detection of picornavirus RNA (75%) was found by in situ
hybridization, yet in a restricted number of palatine tonsil tissues
from patients with chronic tonsillar disease. Of note, that study
pointed towards a role for HRV in pathogenesis of chronic
tonsillitis based on the analysis of tissues from 4 patients.
Moreover, the in situ hybridization signal attributed to HRV,
could have been caused by persistent HEV. The specificity of our
findings is supported by the TaqMan technology, which relies on
the hybridization of a fluorescent probe internal to the amplicon,
bringing reliability to the differentiation between HRV and HEV.
Detection of picornaviruses in that study appeared to be more
frequent in patients with chronic tonsillitis than in patients with
recurrent tonsillitis, what is in agreement with our observations.
Not surprisingly, HAdV was the most frequently detected agent,
present in near one half of all patients when results from all sample
sites were taken together; and in over 42% considering only
macerated adenoid tissues. In fact, HAdV was first identified in
association with adenoid tissue [8], and our findings confirm the
strong tropism of that agent for lymphoepithelial tissues. Although
the molecular details of HAdV persistency are not completely
understood [15], the prolonged presence of this agent in
nasopharyngeal tonsils allows for periodic and asymptomatic virus
shedding that ensures successful transmission with infection of vast
proportions of humans at some point in life [16,17].
HBoV is a recently identified parvovirus, found in association
with respiratory and gastrointestinal disorders [18,19]. We have
shown previously that only approximately 25% of patients with
detectable HBoV genome shed mRNA, a marker of active viral
replication [20], indicating that a significant proportion of infected
HBoV-patients carry the virus in a latent/persistent state. This is
indirectly supported by the fact that bocaviruses of other species
can persist in lymphoid tissues of the upper respiratory tract,
indicating that HBoV could persist in humans in a similar way and
be related to chronic inflammation of these tissues. In fact, a recent
flow cytometry study has shown that HBoV can be detected in
tonsillar lymphocytes in 32% of pediatric patients who underwent
tonsillectomy [13]. In agreement with that, the presently reported
study found HBoV in nearly 24% of the adenoids, and further
expanded to reveal that HBoV is more likely to be detected in in
adenoids than in palatine tonsils or nasopharyngeal secretions,
suggesting a preference for adenoids over palatine tonsils and thus
bringing new insights to the pathogenesis of this emergent virus.
This is the first report of viral co-infection in chronic
adenotonsillar diseases, and it is notable that two thirds of the
patients had more than one respiratory virus detected simulta-
neously, even in the absence of symptoms and signs of acute
respiratory infection. The majority of viral co-infections resulted
from combinations of HAdV, HBoV, HEV and HRV, and co-
infections were more frequent when detections of viruses both in
tissues and nasopharyngeal secretions were considered. When only
adenoids and palatine tonsils were analyzed, rates of viral
coinfections were close to 45% and 21%, respectively.
The presently reported findings on co-infections are similar to
what has been known for acute respiratory infections, which can
yield as much as 40% to 70% of virus co-detection [21,22]. Martin
et al have shown that viral co-infections rates are higher in patients
with HBoV and HAdV than in those with HRV and other RNA
viruses. They reported rates of co-infections of 72% in patients
with HBoV, and of 33% in patients with HRV.
No clear associations were found between any particular virus
and clinical features. However, it should be pointed out that there
was a high frequency of virus detection, especially HEV, in highly
hypertrophic tissues. This is in keeping with results published for
EBV [4], showing a significant difference in frequency of positive
results for EBV by in situ hybridization in younger patients with
higher degrees of palatine tonsil hypertrophy than in older patients
with a lower degrees of hypertrophy.
While mechanisms that might underlie a link of the presence of
prolonged viral infection in tonsils with chronic tonsillar diseases, it
is tempting to speculate that virus products may function as
pathogen-associated molecular patterns (PAMPs), that would
maintain inflammation by the stimulation of the innate immunity,
with continuous processes of damage and repair, thus leading to
hyperplasia and hypertrophy of tonsils, whose enlarged sizes would
cause clinical features of chronic tonsillar disease. This finds
support on histological studies of enlarged tonsils, which reveals
enlargement of follicles, indicating hyperplasia with marked
increase in the numbers of lymphoid cells in the germinal centers
[23]. On the other hand, it is possible that some respiratory viruses
may directly affect tonsil cell survival, by counteracting natural
mechanisms of cell death, including apoptosis. Reduction in
lymphoid cell apoptosis is accepted as an important mechanism in
the pathogenesis of tonsillar hypertrophy [24], and that could be
caused by viruses, such as the case of human coronavirus, which
has a nonstructural protein that inhibits apoptosis triggered by the
mitochondrial antiviral signaling adaptor (MAVS) [25].
In summary, the present study has shown that a very high
proportion of patients with chronic adenotonsillar diseases harbor
at least one respiratory virus, and that these agents are frequently
detected in adenotonsillar tissues. The patients were sampled only
once, which hampers determination of the duration of virus
presence in them. Nevertheless, significant proportions of such
patients had different combinations of viruses simultaneously
detected at different sites, suggesting that some of them might be
persistent. It is remarkable that not all respiratory viruses were
detected at similar frequencies in adenoids and palatine tonsils, nor
were uniformly shed in nasopharyngeal secretions. Specific viruses
seem to preferentially infect some tissues, such as human
enteroviruses that were more often detected in palatine tonsils
than in adenoids, and were shed in secretions much less frequently
than all others. Taken together, these data suggest that respiratory
virus persistence/latency may play roles in pathogenesis of chronic
adenotonsillar diseases, and that these tissues may serve as inter-
seasonal virus reservoirs, with possible impact in transmission in
the community.
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